Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 32 of 36.
Jul 2011
19 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 56691 lacs for quarter ending on 30-JUN-2011 against Rs. 55423 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 15293 lacs for the quarter ending on 30-JUN-2011 against Rs. 19864 lacs for the quarter ending on 30-JUN-2010.19 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 117351 lacs for quarter ending on 30-JUN-2011 against Rs. 105509 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 22982 lacs for the quarter ending on 30-JUN-2011 against Rs. 19918 lacs for the quarter ending on 30-JUN-2010.6 Jul · Board meeting
To consider amongst others unaudited financial results for the quarter ended June 30, 2011.
Jun 2011
May 2011
14 May · Dividend
Company shall make the payment of dividend of Rs. 6.25 (125%) on 20,47,48,520 equity shares of Rs. 5/- each on July 25, 2011 subject to the approval of the same by the shareholders at the ensuing Annual General Meeting scheduled to be held on July 19, 2011.9 May · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 11, 2011 to July 19, 2011 (both days inclusive) for the purpose of payment of dividend for the year ended March 31, 2011. Further, the Annual General Meeting of the Company will be held on July 19, 2011.6 May · Management
Board of Directors at its Meeting held on May 06, 2011 appointed Mr. Nitin Raojibhai Desai as an Additional Director. He is a Non- Executive and Independent Director on the Board w.e.f. May 06, 2011.6 May · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 446467 lacs for year ending on 31-MAR-2011 against Rs. 357418 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 71100 lacs for the year ending on 31-MAR-2011 against Rs. 50514 lacs for the year ending on 31-MAR-2010.6 May · Dividend
Board of Directors of the Company at its meeting held on May 06, 2011 have recommended a dividend of Rs.6.25/- [@ 125%] per equity share on 204,748,520 equity shares of Rs.5/- each for the financial year ended on March 31, 2011.6 May · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 217623 lacs for year ending on 31-MAR-2011 against Rs. 183293 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 61038 lacs for the year ending on 31-MAR-2011 against Rs. 50327 lacs for the year ending on 31-MAR-2010.
Apr 2011
25 Apr · Board meeting
To consider amongst others audited financial results for the year ended on March 31, 2011 and recommend the dividend on equity shares for the year ended March 31, 2011.6 Apr · Results
Company proposes to submit audited financial results for the entire financial year ended on March 31, 2011 instead of providing unaudited financial results for the quarter ended on March 31, 2011. In view of the above, the Company shall provide to the exchange audited financial results for the year ended March 31, 2011 within sixty days of the end of the financial year March 31, 2011.
Feb 2011
8 Feb · Rating
CRISIL has assigned a 'AA+/Stable' (pronounced 'double A plus with stable outlook') rating for the Rs.2500 Million Non-Convertible Debenture Programme of the Company. This rating indicates high degree of safety with regard to timely payment of interest and principal on the instrument
Jan 2011
18 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 54213 lacs for quarter ending on 31-DEC-2010 against Rs. 46040 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 14038 lacs for the quarter ending on 31-DEC-2010 against Rs. 12532 lacs for the quarter ending on 31-DEC-2009.18 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 113455 lacs for quarter ending on 31-DEC-2010 against Rs. 96540 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 16201 lacs for the quarter ending on 31-DEC-2010 against Rs. 12967 lacs for the quarter ending on 31-DEC-2009.12 Jan · Demise of Director
Shri Pranlal Bhogilal, an Independent Director of the Company expired and therefore ceased to be a Director of the Company. He was the Chairman of the Investors' Grievance Committee and also member of Audit Committee.6 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter/ nine months ended December 31, 2010.
Oct 2010
19 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 57503 lacs for quarter ending on 30-SEP-2010 against Rs. 48151 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 18160 lacs for the quarter ending on 30-SEP-2010 against Rs. 12440 lacs for the quarter ending on 30-SEP-2009.19 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 110632 lacs for quarter ending on 30-SEP-2010 against Rs. 91258 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 17084 lacs for the quarter ending on 30-SEP-2010 against Rs. 13192 lacs for the quarter ending on 30-SEP-2009.11 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/ half-year ended September 30, 2010.
Sep 2010
Aug 2010
Jul 2010
27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 55423 lacs for quarter ending on 30-JUN-2010 against Rs. 46527 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 19864 lacs for the quarter ending on 30-JUN-2010 against Rs. 12256 lacs for the quarter ending on 30-JUN-2009.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 105509 lacs for quarter ending on 30-JUN-2010 against Rs. 88031 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 19918 lacs for the quarter ending on 30-JUN-2010 against Rs. 12479 lacs for the quarter ending on 30-JUN-2009.9 Jul · Board meeting
Inter alia, to consider unaudited financial results for the quarter ended June 30, 2010
Jun 2010
May 2010
25 May · Updates
Cadila Healthcare Limited had informed the Exchange regarding Zydus Cadila and Abbott had entered a strategic agreement to enhance their competitiveness in the emerging markets. The company has now informed the Exchange vide its letter dated May 25, 2010 that : "As per this agreement, Zydus Cadila has received today from Abbott a milestone payment of US$ 10 mio (Rs. 47.36 Crores)."
Apr 2010
29 Apr · Updates
Disclosure of balance Sheet items in respect of audited standalone financial results of Company for the year ended on March 31, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Updates
Statement of Appropriations pursuant to clause 20 of the Listing Agreement in respect of Annual Audited Financial Results of the Company for the year ended March 31, 2010. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 19, 2010 to July 24, 2010 (both days inclusive) to determine the entitlement of membership of the Company for the payment of dividend as may be declared by the members at the Annual General Meeting of the Company to be held on July 27, 2010.